Form 4: ADC Therapeutics SA Director Viviane Monges Reports Acquisition and Disposal of Common Shares

Director Viviane Monges reports acquiring 40,000 common shares and disposing of shares, with a resulting beneficial ownership of 108,064 shares.

Summary

• On June 13, 2024, Viviane Monges, a director of ADC Therapeutics SA, reported a transaction involving the company's common shares.
• Monges acquired 40,000 common shares through an annual grant of restricted stock units (RSUs) under the Issuer's 2019 Equity Incentive Plan for service as a Director.
• The RSUs were granted at a price of $0.
• These RSUs vest one year from the grant date, contingent upon continued service to the Issuer.
• Each RSU represents a contingent right to receive one share of ADC Therapeutics SA's common stock.
• Following the reported transaction, Monges beneficially owns 108,064 common shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transaction reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting period of one year encourages continued service and commitment from the director.

Future Outlook

The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer.

Industry Context

This filing is a routine disclosure related to director compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the alignment of management's interests with shareholders'.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units to incentivize their directors.
• The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and ownership.
• It aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and performance.

Key Dates